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Abstract 
Objectives: To assess the occurrence of non-motor features and symptom progression in 
patients with uncertain Parkinsonism and Scans Without Evidence of Dopaminergic Deficit 
(SWEDDs), patients with early Parkinson’s disease (PD), and healthy controls. 
Methods: Non-motor data for 62 patients with SWEDDs, a cross-matched sample of PD 
patients (n=62) and a population of healthy controls (n=195) were accessed from the 
Parkinson’s Progressive Marker’s Initiative (PPMI). Data included scores from seven 
validated clinical questionnaires examining a range of non-motor features including 
sleepiness, geriatric depression, REM sleep behaviour, State-Trait anxiety, autonomic 
function and olfactory function. All non-motor symptoms were compared among subjects at 
baseline, one year and two years of follow up.  
Results: SWEDDs had more excessive daytime sleepiness than both PD and healthy subjects 
(p value <0.001) and also had worse cardiovascular and thermoregulatory dysfunction (p 
value = 0.031 and p value = 0.019) compared to PD. SWEDDs had a significantly better 
sense of smell than PD patients (p value <0.001) but worse olfaction than healthy controls (p 
value = 0.005). There was a positive correlation between sleepiness and autonomic 
dysfunction in SWEDDs patients (Spearman’s Rank R=0.502 p<0.001). Follow up analysis 
of patient groups showed stable non-motor phenotypes with no significant fluctuation in 
questionnaire scoring over two years.  
Conclusion: At an early symptomatic stage, SWEDDs exhibit non-motor features that differ 
from PD patients involving cardiovascular, olfactory, sleep and thermoregulatory function. 
Our results suggest that the use of questionnaires to identify non-motor symptoms may help 
differentiate SWEDDs from PD patients at the time of diagnosis.  
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Introduction 
Imaging dopaminergic function has identified a subset of patients who, despite manifesting 
symptoms and signs suggestive of Parkinson’s disease (PD), have normal dopaminergic 
function. These patients have been labelled as having Scans Without Evidence of 
Dopaminergic Deficit (SWEDDs) and represented 4-15% of patients diagnosed with 
idiopathic early PD across clinical trials.(Fahn, 2005) Evidence suggests that SWEDDs do 
not have PD pathology: not only does the nigrostriatal function of SWEDDs patients remain 
normal over 2-5 years follow-up, but most do not deteriorate or respond to Levodopa 
therapy.(Fahn, 2005),(Mian, Schneider, Schwingenschuh, et al., 2011) A number of studies 
have identified adult onset dystonic tremor as one cause of SWEDDs with patients being 
misdiagnosed with PD despite exhibiting clinical features of dystonia.(Schwingenschuh, 
Bhatia, Schneider, et al., 2010),(Schneider, Edwards, Mir, et al., 2007) Essential tremor, 
vascular parkinsonism, and drug-induced parkinsonism should also be considered as 
diagnoses in patients with parkinsonism who are SWEDDs.(Bajaj, 2010) 
While the motor symptoms of SWEDDs mimic those occurring in PD patients, little is known 
regarding the non-motor features of this population. Previous studies have found SWEDDs to 
have significantly fewer non-motor symptoms(Jang, Ahn & Kim, 2013),(Schwingenschuh, 
Bhatia, Schneider, et al., 2010) and significantly better olfaction than PD patients.(Silveira-
Moriyama, Schwingenschuh, O’Donnell, et al., 2009a) Moreover, while non-motor 
symptoms worsen over time in PD patients,(Antonini, Barone, Marconi, et al., 2012) no 
reports on the progression of non-motor symptoms in SWEDDs are available.  
The aims of this study were to document the prevalence and progression of non-motor 
symptoms in SWEDDs in comparison with dopamine deficient PD patients and further 
augment our knowledge and classification of this population. 
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Methods 
Subjects and protocol 
Our study investigated a random sample of de novo PD patients with abnormally reduced 
striatal dopamine transporter (DAT) imaging, a cohort of SWEDDS with features of 
parkinsonism but normal DAT imaging, and healthy controls with normal DAT binding 
enrolled in the Parkinson’s Progression Markers Initiative (PPMI), an ongoing multicentre 
study, (www.ppmi-info.org/data). Data for baseline assessment was accessed on 14.01.2014 
from the PPMI database and data for follow up analysis was downloaded on the 03.07.2014 
to allow more time for patients to progress to two years follow up. PPMI – a public-private 
partnership – is funded by the Michael J. Fox Foundation for Parkinson’s Research and 
funding partners, including Abbvie, Avid radiopharmaceuticals, Biogen idec, Bristol-Myers 
Squibb, Covance, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeck, Merck, 
Meso Scale Discovery, Pfizer, Piramal, Roche and UCB. 
The main eligibility criteria for both PD and SWEDDs patients included the presence of at 
least two of: resting tremor, bradykinesia and rigidity or asymmetric resting tremor and 
asymmetric bradykinesia according to U.K. Brain Bank criteria for the diagnosis of PD.(Gibb 
& Lees, 1988) At baseline patients were required to have had a diagnosis for less than two 
years and be at a Hoehn and Yahr stage of 1-2. Participants were aged over thirty and were 
not expected to require PD medication within six months from baseline. Patients with and 
without striatal dopamine transporter binding deficits present on FP-CIT SPECT (DatScan™) 
were classified as PD or as SWEDDs patients, respectively.  
Study variables 
We utilised a number of validated clinical questionnaires to assess non-motor symptoms in 
study participants. Sleep disorders were rated with the Epworth Sleepiness Scale for the 
severity of excessive daytime sleepiness (EDS) and the REM Sleep Behaviour Disorder 
Screening Questionnaire (RBDSQ) for REM Sleep Behaviour Disorder (RBD).REF 
Depressive symptoms were assessed using the short version of the Geriatric Depression Scale 
(15-item), which we present alongside the number of patients either diagnosed with 
depression or taking antidepressants. The State-Trait Anxiety Inventory for adults scored the 
participants current and general anxiety levels. The Scales for Outcomes in Parkinson’s 
Disease- Autonomic (SCOPA-AUT) Patient Questionnaire measured autonomic dysfunction 
as a function of six individual domains: gastrointestinal, urinary, cardiovascular, 
thermoregulatory, pupillary and sexual. Symptoms assessed include swallowing difficulties 
and bowel problems in the gastrointestinal domain, retention, incontinence and frequency in 
the urinary domain, light-headedness and fainting in the cardiovascular domain, difficulties in 
tolerating heat and cold in the thermoregulatory domain, sensitivity to light in the pupillary 
domain and finally maintaining arousal and achieving orgasm in the sexual domains. The 
MDS-UPDRS 1 scored non-motor symptoms REF and the University of Pennsylvania Smell 
Identification Test (UPSIT) measured olfactory function in participants. 
The presence of excessive daytime sleepiness (EDS) was defined by a score >10 on the 
Epworth Sleepiness Scale.(Johns, 1991) REM Sleep behaviour disorder was diagnosed using 
a cut off value of 5 on the RBDSQ.(Stiasny-Kolster, Mayer, Schäfer, et al., 2007) A GDS 
threshold value of 5 suggested the presence of depressive symptoms.(D’Ath, Katona, Mullan, 
et al., 1994) For the UPSIT we classified hyposmia as >2SDs below the healthy controls 
(HC’s) mean and anosmia as below a score of 18 out of 40.(Deeb, Shah, Muhammed, et al., 
2010) For the SCOPA-AUT, patients using a catheter were given 3 points for each urinary 
question and those who reported a question concerning sexual functions as not applicable, 
were removed from the analysis of sexual dysfunction. As a result, we also report the mean 
SCOPA-AUT total with the sexual analysis excluded. 
We used data from the Clinical Diagnosis and Management Questionnaire which was used as 
part of the PPMI protocol to assess the progression of SWEDDs patients. We focused on the 
study doctors’ clinical diagnoses of the SWEDDs patients. 
 
Statistical analysis 
Continuous variables are expressed as mean ± standard deviation. Normality of data 
distribution was interrogated using the Kolmogorov-Smirnov test. Non-normally distributed 
data was compared across the three subject groups by the use of Kruskal-Wallis test, applying 
a Bonferroni correction for the multiple comparisons performed. Categorical variables were 
expressed as proportions and differences compared with a χ2 test. Correlations between 
variables were investigated by the use of Spearman’s rank correlation coefficient. Follow up 
analysis was performed for each diagnostic group separately, with the study visit being the 
independent variable. All data were interrogated with SPSS version 22.0 (SPSS, Inc., 
Chicago, Illinois). Statistical significance was accepted at p <0.05. 
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Results 
Baseline analysis of non-motor symptoms 
Baseline data for 62 SWEDDs patients, a cross-matched group of 62 PD patients and 195 
healthy controls were compared. Patients were matched for age, gender, disease duration and 
Hoehn and Yahr staging; their baseline characteristics are reported in Table 1. Table 2 details 
the mean questionnaire totals with Kruskal-Wallis derived p values for non-motor symptoms.  
7.2% of healthy controls, 30.6% of SWEDDs and 8.1% of PD patients had excessive daytime 
sleepiness (EDS). Pearson’s Chi-square test revealed there was a significantly higher 
prevalence of EDS in SWEDDs than PD patients (χ2 (1,N=124)=10.127, p=0.001) and 
healthy controls (χ2 (1,N=257)=23.145, p<0.001). PD patients and healthy controls had the 
same prevalence of EDS (χ2 (1,N=257)=0.054, p=0.817). SWEDDs patients had significantly 
more severe daytime sleepiness than both healthy controls and PD’s (p=0.001 and p=0.01).  
The prevalence of REM Sleep Behaviour Disorder (RBD) was 20% in HC’s, 41.9% in 
SWEDDs and 41.9% in PD patients. There was a greater frequency of RBD in SWEDDs than 
HC’s (χ2 (1,N=257)=11.980, p=0.001). SWEDDs had more severe REM Sleep Behaviour 
Disorder than the healthy controls (p=0.001) but similar to Parkinson’s patients (p=1). PD 
patients also had more severe RBD than HC’s (p=.047). In this cohort of patients, 1 HC, 2 
SWEDDs and 1 PD patient had a previous diagnosis of RBD. 6.7% of HC’s had features of 
depression compared to 30.6% of SWEDDs patients and 14.5% of PD’s patients. There was a 
significant increase in the frequency of depressive features in SWEDDs and PD patients χ2 
(1,N=124) =4.613, p=0.032. PD patients did not however have greater depressive features 
than HC’s χ2 (1,N=257) =3.703, p=0.054. SWEDDs had significantly more severe depressive 
symptoms than healthy controls (p=0.001) but not more so than PD patients (p=1). The PD 
patients had increased depressive features compared to HC’s (p=.001). PPMI data showed a 
number of patients to have a formal diagnosis of depression (23 HC’s, 16 SWEDDs and 12 
PD) yet a larger number were taking medication for the treatment of depression (29 HC’s, 17 
SWEDDs and 16 PD). 
The State Trait Anxiety Inventory has two components Y1 (State anxiety) and Y2 (Trait 
anxiety). SWEDDs patients had more severe state and trait anxiety symptoms than HC’s 
(p<0.001 and p<0.001) but their levels were not different from PD patients (p=1 and p=0.9). 
PD patients had higher anxiety than HC’s on both state and trait features (p<0.001 and 
p=0.008). 
SWEDDs had a higher SCOPA total score (after excluding sexual function) than both HC’s 
and PD patients, but only the interaction with HC’s was significant (p<0.001 and p=0.336). 
PD patients also had worse autonomic dysfunction than healthy controls (p<0.001). The 
prevalence of autonomic symptoms and the mean totals for the SCOPA-subdomains are 
shown in Table 3, the p values included represent the inter-group variance in the prevalence 
of autonomic symptoms as assessed by Pearson’s Chi-Square test. Analysis of SCOPA-AUT 
subdomains revealed that pupillary was the only domain that did not vary significantly across 
groups (p=0.011). For urinary, thermoregulatory and sexual domains SWEDDs had 
significantly more dysfunction than healthy controls (all p values <0.001) but were similar to 
PD patients (p=0.906, p=0.019 and p=0.067). This differed from the gastrointestinal and 
cardiovascular domains where SWEDDs patients were more severely affected than healthy 
controls (both p values <0.001) and PD patients (p<0.001 and p=0.001). PD patients had 
worse gastrointestinal, urinary and cardiovascular problems than healthy controls (p<0.001, 
p=0.011 and p=0.001) but did not differ from healthy controls in thermoregulatory and sexual 
domains (p=0.207 and p=0.839).  
The MDS-UPDRS-1 Patient questionnaire contains seven questions concerning non-motor 
symptoms. We found that both SWEDDs and PD patients had a higher severity of these 
symptoms than healthy controls (both p values <.001) but did not differ significantly from 
each other (p=0.268). PD patients also suffered from more severe symptoms than healthy 
controls (p<0.001). 
19.4% of SWEDDs patients had hyposmia in comparison to 72.6% of PD patients, this 
difference in prevalence was significant, χ2 (1,N=124) =35.359, p<0.001. There was also a 
significant difference in the frequency of anosmia between the two groups, with 4.8% of 
SWEDDs patients reporting loss of sense of smell compared to 29% of PD patients, χ2 
(1,N=124) =12.90, p<0.001. SWEDDs had worse hyposmia than healthy controls (p=.005), 
but a significantly better sense of smell than Parkinson’s disease patients (p<.001). PD 
patients had significantly worse hyposmia than healthy controls (p<0.001). 
These was a correlation between ESS and SCOPA-AUT scores between ESS total and 
SCOPA-total (Spearman’s Rank R=0.523 p<0.001) for SWEDDs patients but only a weak 
correlation for PD patients (Spearman’s Rank R=0.280 p=0.028). ESS totals were most 
strongly correlated in SWEDDs patients with thermoregulatory (R=0.532 p<0.001), pupillary 
(R=0.401 p=0.001) and urinary domains (R=0.376 p=0.031). 
 
Follow up analysis of non-motor symptoms 
At the time of analysis, 128 healthy controls, 30 SWEDDs patients and 36 of the PD patients 
analysed at baseline also had data recorded after one year and two years of follow up. Table 4 
outlines participants’ mean totals for the clinical questionnaires at each time point (UPSIT 
was not included as it was only recorded in patients at baseline) and p values representing the 
variation in questionnaire scoring over the course of the study visit. We found no significant 
variation in scoring for any clinical questionnaire or diagnostic group over this time period.  
 
Clinical Diagnosis and Management Questionnaire 
Figure 1 details the assigned diagnoses of the SWEDDs patients after their most recent visit. 
There were 7 categories and one third were still labelled as IPD. The ‘Other’ category 
contained one case of valproic acid induced parkinsonism, one case of asymmetric 
bradykinesia, one case of asymmetric postural tremor, one functional disorder, three cases 
relating to neuropathy, one case of Primary Lateral Sclerosis, one possible dementia, two 
cases of unspecified parkinsonism and one case of dystonic tremor.  
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Discussion 
Our study showed that SWEDDs patients had more severe levels of sleepiness, depressive 
symptoms, REM Sleep Behaviour Disorder, both state and trait anxiety, autonomic 
dysfunction and a worse sense of smell than healthy controls at baseline. They also 
experienced significantly worse sleepiness, gastrointestinal and cardiovascular dysfunction 
compared to PD patients, although they had better olfaction. 
Previous research into sleep abnormalities in PD(Gjerstad, Alves, Wentzel-Larsen, et al., 
2006),(Gjerstad, Aarsland & Larsen, 2002),(Zoccolella, Savarese, Lamberti, et al., 2011) has 
suggested an EDS prevalence of 5.6-8% at baseline, which is concordant with the prevalence 
of 8.1% in PD patients. Circadian rhythm has an important function in sleep regulation and 
may be mediated by the autonomic nervous system(Morris, Aeschbach & Scheer, 2012) and 
therefore irregularities of autonomic functioning may contribute to sleep disorders. Although 
overall autonomic function in SWEDDs was not significantly worse than PD patients, the 
stronger correlation between autonomic function and sleepiness levels in SWEDDs patients 
may partially account for their greater levels of excessive daytime sleepiness than PD 
patients. 
Our study reports greater levels of RBD in SWEDDs and PD patients than healthy controls 
but no difference between PD patients and SWEDDs. There is an absence of research into 
RBD in SWEDDs patients, but previous studies into the prevalence of RBD in PD have 
shown RBD to be present in 25-40% of patients.(Chahine, Daley, Horn, et al., 2013a) Two 
recent studies of over 400 PD patients, one using video supported polysomnography and one 
using the RBDSQ to diagnose RBD, found the overall frequency of RBD to be 45-
47%.(Sixel-Döring, Trautmann, Mollenhauer, et al., 2011),(Rolinski, Szewczyk-Krolikowski, 
Tomlinson, et al., 2014) In line with these findings, we found that 41.9% of PD patients in 
this cohort had RBD. The precise pathological mechanisms underlying RBD are still 
unknown but dopamine dysfunction is not thought to be the sole factor,(Iranzo, Santamaria & 
Tolosa, 2009) instead abnormal functioning in glutamatergic, GABAergic, serotonergic and 
noradrenergic pathways are thought to be involved.(Iranzo, Santamaria & Tolosa, 
2009),(Lima, 2013). Depression is a symptom often unrecognised in PD(Weintraub, Moberg, 
Duda, et al., 2003) and contributes to functional disability in daily living.(Ravina, Camicioli, 
Como, et al., 2007) The frequency of depressive features at 14.5% in the PD cohort is 
comparable to the 13.8% reported by Ravina et al,(Ravina, Camicioli, Como, et al., 2007) in 
their study of depression in PD patients using the GDS-15. Depression in SWEDDs patients 
has not previously been investigated in depth, although research by Jang et al,(Jang, Ahn & 
Kim, 2013) seems to suggest that SWEDDs patients with depression are less severely 
affected than depressed PD patients. In contrast, our findings suggest a higher occurrence of 
depression in SWEDDs patients than in PD patients but that the severity of depression did not 
differ between these groups. Discrepancies between ours and Jang et al’s results may be 
explained by our larger sample size and use of the GDS-15 rather than the Non-Motor 
Symptoms Scale (NMSS), with the GDS-15 being a dedicated and validated questionnaire for 
detecting depressive features in Parkinson’s Disease.(Ertan, Ertan, Kiziltan, et al., 2005) 
State and trait anxiety results for PD patients were consistent with one study of 46 PD 
patients(Mondolo, Jahanshahi, Granà, et al., 2007) but inconsistent with another,(Yamanishi, 
Tachibana, Oguru, et al., 2013) the differences may be accounted for by a combination of our 
lower mean disease duration, (0.69 vs 8.3 yrs) lower proportion of female patients (38.7% vs 
60.7%) and patient drug naivety.  
Autonomic symptoms were present across study groups, with gastrointestinal, urinary and 
thermoregulatory domains being the most common. A study into non-motor symptoms in de 
novo PD(Mollenhauer, Trautmann, Sixel-Döring, et al., 2013) found scores for the SCOPA-
AUT subdomains that are not dissimilar to ours. In the cardiovascular and gastrointestinal 
domains, SWEDDs were more severely affected than PD patients. Jang and colleagues(Jang, 
Kim, Cho, et al., 2013) used MIBG myocardial scintigraphy to investigate cardiac 
sympathetic nerve denervation in SWEDDs and PD patients and found that SWEDDs were 
less affected than PD patients, but more so than controls.  These findings would suggest that 
the cardiovascular complaints in the SWEDDs cohort are not related to cardiac sympathetic 
denervation, this, however, remains to be further investigated. Work by Cersosimo & 
Benarroch(Cersosimo & Benarroch, 2012) has suggested that autonomic dysfunction in 
neurodegenerative diseases may partly reflect Lewy-Body pathology in the autonomic 
nervous system. It remains to be ascertained if this is also the case in SWEDDs patients. 
Silveira and colleagues’(Silveira-Moriyama, Schwingenschuh, O’Donnell, et al., 2009b) 
investigation into olfaction in SWEDDs patients showed SWEDDs to have a normal sense of 
smell, significantly better than that of PD patients. Our study also found that SWEDDs had a 
better sense of smell than PD patients but differs in that olfaction in SWEDDs was worse 
than in healthy controls. The strength of our study is in our larger SWEDDs population, 
although we did not account for smoking status or other factors that can affect olfaction. 
The working diagnoses of the SWEDDs patients are consistent with suggested causes of the 
SWEDD phenotype.(Bajaj, 2010) This study is not sufficiently powered to assess non-motor 
symptoms in the individual diagnostic groups of SWEDDs patients, but it has shown the 
stability of non-motor symptoms in all patient groups over a two-year follow up period, a 
finding already documented in PD patients.(Erro, Picillo, Vitale, et al., 2013) 
Limitations of our study include that medication status was not taken into account for the 
follow up analysis but, given the lack of significant results, it is unlikely to have had a 
confounding influence. Moreover due to the ongoing nature of the PPMI study, data was not 
yet available for all patients at follow up, which somewhat restricted the size of the study 
population. In addition, the standard of truth for the working diagnoses of the SWEDDs 
patients was the clinical assessments of the study doctors. Finally, whilst a cut-off value of 5 
for the RBDSQ may be most appropriate when investigating both PD patients and 
HC’s,(Chahine, Daley, Horn, et al., 2013b) because the questionnaire scores the presence of 
parkinsonism, it may overestimate the frequency of RBD in SWEDDs and PD patients. 
In conclusion, our study has demonstrated a stable spectrum of non-motor symptoms in 
SWEDDs and PD over a two year follow up period. Our results suggest a difference between 
SWEDDs and early PD patients in key domains, particularly in daytime somnolence which is 
more severe and olfactory function which is only mildly affected. Further research should 
focus upon the pathological basis of SWEDDs parkinsonism and in vivo imaging of both 
dopaminergic and non-dopaminergic systems for a better understanding of the SWEDDs 
phenotype. This in turn will help classify SWEDDs patients correctly and differentiate them 
from PD and other forms of parkinsonisms. 
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TABLE 1: Baseline characteristics of study participants (Mean ± SD) 
Variables 
Diagnosis 
Healthy controls  SWEDDs Parkinson’s Disease 
Participants (n) 195 62 62 
Age (yr) 63.0 ± 11.1a 62.5 ± 10.0a 63.3 ± 9.1a 
Gender (%) Female 35.9% 38.7% 37.1% 
Male 64.1% 61.3% 62.9% 
Disease duration (yr)   0.62 ± 0.67a 0.69± 0.70a 
Hoehn and Yahr 
Stage (n) 
1  36 28 
2  26 33 
3  0 1 
Note: Values in the same row sharing the same subscript are not significantly different at p< 
0.05 in the two-sided test of equality for column means. Tests assume equal variances. 
 
 
 
 
  
 
 
TABLE 2 Baseline questionnaire totals 
 
Diagnosis 
Healthy Controls 
(n=195) 
SWEDDs 
(n=62) 
Parkinson’s Disease 
(n=62) 
 
Mean ± SD Mean ± SD Mean ± SD p values 
ESSa 5.63±3.71 8.15±4.81 5.61±3.48 .001 
GDSb 1.29±2.10 3.39±3.66 2.27±2.57 <.001 
RBDSQc 2.68±1.77 4.58±2.90 4.27±2.71 .001 
STAI Y1d 26.55±7.58 35.16±9.46 34.18±10.81 <.001 
STAI Y2e 27.40±5.33 34.89±9.91 33.42±9.99 <.001 
SCOPA-AUTf 5.08±3.28 12.21±8.68 8.79±5.52 <.001 
MDS-UPDRS 1g 2.38±2.44 6.42±4.88 4.21±2.67 <.001 
UPSITh 35.03±4.44 31.26±6.30 21.82±8.12 <.001 
a. Epworth Sleepiness Scale 
b. Geriatric Depression Scale Short  
c. REM Sleep Behaviour Disorder Screening Questionnaire 
d. State-Trait Anxiety Inventory. Y1=State anxiety 
e. State-Trait Anxiety Inventory. Y2= Trait anxiety 
f. SCales for Outcomes in PArksinson's-AUTonomic (Excluding sexual domain) 
g. MDS-UPDRS Patient Questionnaire One 
h. University of Pennsylvania Smell Identification Test 
 
 
 
TABLE 3: Baseline prevalence (%) and severity of autonomic symptoms (Mean ± SD) 
Domain Healthy controls SWEDDs Parkinson’s Disease X2 p value 
 Prevalence Severity Prevalence Severity Prevalence Severity  
Gastrointestinal 40.0% 0.68±1.02 77.4% 3.06±3.09 82.3% 2.27±1.95 .001* 
Urinary 91.8% 3.07±2.14 100% 4.98±3.35 93.5% 4.40±3.19 .067 
Cardiovascular 15.9% 0.18±.45 56.5% 1.08±1.42 38.7% 0.52±0.74 .001* 
Thermoregulatory 52.3% 0.86±1.07 74.2% 2.45±2.41 66.1% 1.21±1.33 .004* 
Pupillary 26.2% 0.3±0.5 43.5% 0.6±0.9 32.3% 0.4±0.7 .034* 
Sexuala 41.3% 0.87±1.37 66.0% 1.79±1.75 50.0% 1.07±1.44 .007* 
* Significant at p=0.05 
a For sexual analysis there were 167 HC’s, 53 SWEDDs, 54 PD patients. 
 
 
 
TABLE 4 Clinical questionnaire totals of patients included in follow up analysis (Mean ± SD)  
 
Diagnosis 
Healthy Controls (n=128) SWEDDs (n=30) Parkinson's Disease (n=36) 
Visit Visit Visit 
Baseline Year 1 Year 2 
P 
values Baseline Year 1 Year 2 
P 
values Baseline Year 1 Year 2 
P 
values 
ESSa 5.87±3.40 5.59 ±3.46 5.69±3.62 .809 7.87±5.03 6.70±4.76 6.77±5.05 .593 6.33±3.51 6.89±4.20 7.49±4.99 .760 
GDS-15b 1.34±2.38 1.21±2.14 1.10±1.91 .601 2.90±3.82 2.90±3.16 3.13±2.83 .493 2.06±1.82 2.23±1.78 2.11±2.13 .825 
RBDSQc 2.73±2.19 2.83±2.09 2.59±2.16 .552 4.07±2.64 4.23±2.70 4.03±2.91 .943 4.17±2.63 3.94±2.54 4.62±2.56 .471 
STAI Y1d 27.8±8.01 28.05±9.04 28.20±8.74 .906 35.07±10.36 33.57±11.18 31.97±9.19 .569 34.06±9.68 33.80±10.33 32.95±9.94 .882 
STAI Y2e 29.3±7.42 29.27±8.88 27.82±7.14 .194 35.00±11.37 33.83±10.30 34.27±10.14 .928 31.83±8.09 32.37±9.10 31.27±8.38 .801 
SCOPA-
AUTf 
5.97±3.99 6.16±4.86 6.22±4.65 .964 11.67±9.45 12.43±8.94 12.30±8.53 .700 10.42±5.96 12.57±6.49 12.14±6.65 .238 
MDS-UPDRS 
1g 
2.21±2.48 2.62±2.62 2.52±2.52 .315 5.00±4.42 5.33±4.06 6.17±4.73 .570 4.25±2.45 5.34±3.03 6.05±3.51 .471 
  
 
 
 
 
 
 
 
a. Epworth Sleepiness Scale 
b. Geriatric Depression Scale Short  
c. REM Sleep Behaviour Disorder Screening Questionnaire 
d. State-Trait Anxiety Inventory. Y1=State anxiety 
e. State-Trait Anxiety Inventory. Y2= Trait anxiety 
f. SCales for Outcomes in PArksinson's-AUTonomic 
g. MDS-UPDRS Patient Questionnaire One 
 
 
 
 
